Phase I Dose Escalating Study of TKI258

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of in this study is to assess the safety profile and estimate the maximum tolerated dose of TKI258 in Japanese patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

NCT01270906

Neoplasms Cancer Tumors

TERMINATED PHASE1

Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)

NCT00880568

Neoplasms Malignant

COMPLETED PHASE1

A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

NCT00410358

Advanced Solid Tumors

COMPLETED PHASE1

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

NCT00503477

Advanced Solid Tumor

COMPLETED PHASE1

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors

NCT04805060

Terminal Malignant Tumors

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TKI258

dose escalation

Group Type EXPERIMENTAL

TKI258

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TKI258

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dovitinib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent must be obtained prior to any screening procedures
* Advanced solid tumors
* Agreement to remaining hospitalized
* ECOG performance status of 0 or 1
* Life expectancy of at least 3 months
* Pregnant women. Male and female patients of reproductive potential must agree to employ an effective method of birth control
* Demonstrate the specific hematological /blood chemistry laboratory values

Exclusion Criteria

* Receipt of any investigational compound within 28 days prior to the first dose of study drug or failure to have recovered from the side effects of such prior therapy
* Receipt of other antineoplastic therapy, including chemo-, hormonal, immuno-, and radiation therapy, within 28 days (with some exceptions)
* Patients with CNS and/or leptomeningeal disease metastases
* Presence or history of thromboembolic or cerebrovascular events
* Impaired cardiac function or clinically significant cardiac disease
* Malabsorption syndrome or uncontrolled gastrointestinal toxicities
* Patients known to be HIV- or HBV- or HCV- positive
* Patients with acute or chronic uncontrolled infection
* Patients who have undergone surgery with general anesthesia for any cause within 28 days prior to the first dose of study drug
* Patients who have been receiving anticoagulant therapy
* Receipt of any hematopoietic colony stimulating factor or blood transfusion within 14 days prior to the first dose of study drug
* Patients who have been administering concomitant medication which may prolong the QTc interval
* Patients with interstitial pneumonia or pulmonary fibrosis proven on a chest CT scan
* Patients with a large volume of ascitic and/or pleural fluid which requires drainage
* Patients with any bone fractures
* Deemed otherwise unsuitable by the investigator

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No